Competitor Analysis: Streptococcal Vaccines and Antibodies
Product description
The present Competitive Intelligence Report about Streptococcal Vaccines & Antibodies provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies against infection caused by streptococcus pneumoniae, Group A Streptococcus (GAS) or Group B Streptococcus (GBS) as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-positive, alpha-hemolytic, bile soluble aerotolerant anaerobe, which can attack different parts of the body. When bacteria invade the lungs, they cause the most common form of community-acquired bacterial pneumonia; when bacteria invade the bloodstream, they cause bacteremia; and when they invade the covering of the brain, they cause meningitis. Pneumococci may also cause otitis media (middle ear infection) and sinusitis.
There are two types of pneumococcal vaccine currently available to protect against pneumococcal disease: a polysaccharide vaccine and a conjugate vaccine. The polysaccharide vaccine is used in adults and the conjugate vaccine is used in children. The polysaccharide has been available in the United States for more than 20 years. Since the year 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) is available with tremendous commercial success (2008 sales of (US$ 2.7 bln). This has stimulated strong interest in the vaccine industry and lead to several successor vaccinesand candidates.
The report includes a compilation of currently active projects in development of vaccines and antibodies targeting pneumococcus (Streptococcus pneumoniae), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) for prophylaxis and treatment of streptococcal infections. In addition, the report lists company-specific R&D pipelines of Streptococcal Vaccines & Antibodies. Competitor projects are listed in a tabular format providing information on:
Index
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Streptococcal Vaccines & Antibodies provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies against infection caused by streptococcus pneumoniae, Group A Streptococcus (GAS) or Group B Streptococcus (GBS) as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-positive, alpha-hemolytic, bile soluble aerotolerant anaerobe, which can attack different parts of the body. When bacteria invade the lungs, they cause the most common form of community-acquired bacterial pneumonia; when bacteria invade the bloodstream, they cause bacteremia; and when they invade the covering of the brain, they cause meningitis. Pneumococci may also cause otitis media (middle ear infection) and sinusitis.
There are two types of pneumococcal vaccine currently available to protect against pneumococcal disease: a polysaccharide vaccine and a conjugate vaccine. The polysaccharide vaccine is used in adults and the conjugate vaccine is used in children. The polysaccharide has been available in the United States for more than 20 years. Since the year 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) is available with tremendous commercial success (2008 sales of (US$ 2.7 bln). This has stimulated strong interest in the vaccine industry and lead to several successor vaccinesand candidates.
The report includes a compilation of currently active projects in development of vaccines and antibodies targeting pneumococcus (Streptococcus pneumoniae), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) for prophylaxis and treatment of streptococcal infections. In addition, the report lists company-specific R&D pipelines of Streptococcal Vaccines & Antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- Streptococcus Pneumonia (Pneumococcus)
- Group A Streptococcus
- Group B Streptococcus
- Other
- Streptococcal Vaccine & Antibody R&D Agreements
- Corporate Streptococcal Vaccines & Antibody R&D Pipelines
- About La Merie
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
